https://www.selleckchem.com/pr....oducts/ide397-gsk-43
30, 0.64), 12 months (RR = 0.46, 95%CI 0.30, 0.69), and over 24 months (RR = 0.58, 95% CI 0.35, 0.95) after treatment, compared with those receiving NBI. CBTp was also associated with more reduced attenuated psychotic symptoms by 12 months (SMD = -0.17, 95% CI -0.33, -0.02) and by 24 months (SMD = -0.24, 95% CI -0.43, -0.06). No beneficial effects on functioning, depression, quality of life, or distress were observed favoring CBTp. CBTp is effective in reducing both psychosis transition rates and attenuated psychotic symptoms
Like
Comment
Share
